about
In vivo experience with natural scaffolds for myocardial infarction: the times they are a-changin'Pharmacotherapy for comorbidities in chronic heart failure: a focus on hematinic deficiencies, diabetes mellitus and hyperkalemia.High serum erythropoietin levels are related to heart failure development in subjects from the general population with albuminuria: data from PREVEND.Prevalence, incidence, and prognostic value of anaemia in patients after an acute myocardial infarction: data from the OPTIMAAL trial.Erythropoietin improves long-term neurological outcome in acute ischemic stroke patients: a randomized, prospective, placebo-controlled clinical trialEffect of erythropoietin on level of circulating endothelial progenitor cells and outcome in patients after acute ischemic stroke.EPO improves the proliferation and inhibits apoptosis of trophoblast and decidual stromal cells through activating STAT-5 and inactivating p38 signal in human early pregnancyComparison of acute versus convalescent stage high-sensitivity C-Reactive protein level in predicting clinical outcome after acute ischemic stroke and impact of erythropoietinEffects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer.Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways.Effects of combination of proliferative agents and erythropoietin on left ventricular remodeling post-myocardial infarction.Erythropoietin and myocardial protection: what's new?Molecular biology of apoptosis in ischemia and reperfusion.Erythropoietin improves skeletal muscle microcirculation and tissue bioenergetics in a mouse sepsis modelErythropoietin in chronic heart failure.Darbepoetin-alpha prevents progressive left ventricular dysfunction and remodeling in nonanemic dogs with heart failure.The role of erythropoietin as an inhibitor of tissue ischemia.Multiorgan-protective actions of blockers of the renin-angiotensin system, statins and erythropoietin: common pleiotropic effects in reno-, cardio- and neuroprotection.Effects of erythropoietin on electrocardiogram changes in carbon monoxide poisoning: an experimental study in ratsImpact of epoetin alfa on left ventricular structure, function, and pressure volume relations as assessed by cardiac magnetic resonance: the heart failure preserved ejection fraction (HFPEF) anemia trial.Cellular basis of uraemic cardiomyopathy: a role for erythropoietin?Lessons from genetically altered mesenchymal stem cells (MSCs): candidates for improved MSC-directed myocardial repair.Identification of Methionine Oxidation in Human Recombinant Erythropoietin by Mass Spectrometry: Comparative Isoform Distribution and Biological Activity Analysis.Biologically active recombinant human erythropoietin expressed in hairy root cultures and regenerated plantlets of Nicotiana tabacum L.Cardiac antiapoptotic and proproliferative effect of recombinant human erythropoietin in a moderate stage of chronic renal failure in the rat.An emerging need for developing new models for myocardial infarction as a chronic complex disease: lessons learnt from animal vs. human studies on cardioprotective effects of Erythropoietin in reperfused myocardium.Protective roles of erythropoiesis-stimulating proteins in chronic heart failure with anemia.Erythropoietin: when liability becomes asset in neurovascular repair.Bone marrow dysfunction in chronic heart failure patients.Anaemia is associated with shorter leucocyte telomere length in patients with chronic heart failure.Adequacy of endogenous erythropoietin levels and mortality in anaemic heart failure patients.Erythropoietin combined with ACE inhibitor prevents heart remodeling in 5/6 nephrectomized rats independently of blood pressure and kidney function.Accidental ten times overdose administration of recombinant human erythropoietin (rh-EPO) up to 318,000 units a day in acute myocardial infarction: report of two cases.Histopathological study of erythropoietin protective effect on carbon monoxide-induced cardiotoxicity in rat.Comorbidities in Heart Failure.Anaemia and renal dysfunction are independently associated with BNP and NT-proBNP levels in patients with heart failure.Erythropoietin in cardiorenal anemia syndrome.Effects of Erythropoietin Receptor Activity on Angiogenesis, Tubular Injury and Fibrosis in Acute Kidney Injury: A "U-Shaped" Relationship.Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial.The effect of testosterone on insulin sensitivity in men with heart failure.
P2860
Q26775715-1302AA38-9712-42D8-B9D5-3D61944536D9Q30250020-531AA175-CB80-4DCF-986E-379D5AA70D5BQ31037729-43F63BB4-2CE6-41E1-956E-8B8EEC39FDB3Q33433326-0896E93F-4415-4EAD-98C1-B9AE28DB5B25Q35147461-757563C0-14A9-4629-98F7-ED40E7862996Q35566925-1F441E48-88E7-4E68-9552-0F5EB7049CA2Q35577868-ED3EEB7A-3C05-4694-9A00-50DFA695B845Q35777054-E8219814-F85C-44F9-8AA5-2AC9851725F0Q35858979-5F60A269-65A7-42B1-B3F5-6C783EDF15F4Q35997721-EEA27914-3EA3-4AC4-BCC4-EE97BCB94CD9Q36127313-869205CE-DF9F-43E4-8E3F-FAF669778EFAQ36191300-25924E8C-9A07-43F5-AF99-75E0EBEC35BBQ36327419-A31BD124-F063-4311-998F-C1DE0D131B6EQ36392457-A6134BAF-9999-4289-B173-EE3FE3DEED3AQ36961380-E1405861-733D-4311-AA26-69990C7D4729Q37038709-F1A64E8B-D4F1-4859-9098-46975C403D83Q37195742-A31CCDC8-34EF-4754-B165-5FCB55918FF9Q37247753-AE0A5042-C8EA-4309-A431-E73AF0E64C75Q37268268-E061104F-7C08-43D0-A9F0-04937FF33AD5Q37276822-EF81BCA2-4A56-476A-BC93-495EA97DC912Q37562631-04B0A71E-FA1F-48A3-B0FD-638DD5AD22FFQ37955704-76C69623-A7C9-4030-81B0-772251E8F034Q38616210-A12B1857-A216-4EB5-9CE9-5CF57BC5B006Q41362029-84B808E1-607C-4DA9-9B2B-F15EA9D5EBACQ41398632-63EE553D-CF13-4F78-8AF5-207208205CD3Q41943331-FFD3DA7D-96DA-417D-9582-6B55574DECB4Q42753015-5782A078-52EA-41CC-8A15-E9FB3044C219Q42972651-1647F03B-9321-4B26-9DA5-3A01A9CD613BQ43081654-CA818DDA-B780-4ED8-BB77-F18F1E7155DAQ43119689-797FF3BD-53D4-4F6F-9FD1-3D42EDDD2EDBQ43773570-142586F0-5415-4DC3-85BE-7F9C00F5DA53Q46192933-13251743-4AB6-44A7-83C9-45AFFBD971A8Q46918400-02B92D28-039F-46C0-9B5E-310964FE7EB3Q47142543-F9668D1B-E8F5-42D9-85F0-5A5B58DE8921Q47744924-5237EF90-613A-4618-92A1-C50ED7D1C109Q48154510-2520BC16-3D0E-4FBD-AFDC-D6E6EF9C7B36Q49375907-2481F9F6-843C-47BE-AEC7-C4E7867CF9D1Q49541601-F1ADFC0B-95A8-435D-819C-D226D84BF8FAQ50706724-9B293D69-FA9E-4CEB-B820-0E64E8FC4D97Q51495046-8A0B5F65-8B3E-45A1-93DA-8C4AADA3591B
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Erythropoietin in cardiovascular diseases.
@ast
Erythropoietin in cardiovascular diseases.
@en
type
label
Erythropoietin in cardiovascular diseases.
@ast
Erythropoietin in cardiovascular diseases.
@en
prefLabel
Erythropoietin in cardiovascular diseases.
@ast
Erythropoietin in cardiovascular diseases.
@en
P2093
P1476
Erythropoietin in cardiovascular diseases
@en
P2093
Adriaan A Voors
Erik Lipsic
Peter van der Meer
P304
P356
10.1016/J.EHJ.2003.11.017
P577
2004-02-01T00:00:00Z